The Latest Breaking News from NICE

Isak Jansson, who has been linked with a move to Celtic in recent days, is reportedly set to join Nice.

IN FULL

The best managers in the world, from the tinkermen to the tacticos and everyone in between

ANALYSIS: Paul Atkinson and Sally Sheard say the decision reflects a cautious and evidence-based approach that protects patients and public funds

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for routine NHS use in England. While disappointing for some families affected by dementia, this decision reflects a cautious and evidence-based approach that protects patients and public funds.

IN FULL

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.

Treating lower back pain is enormously expensive. In the UK it’s estimated to cost the NHS around £3.2 billion a year. So, ensuring patients get the right treatment is critical.

IN FULL